Company Overview and News
PayPal Holdings, Inc. (PYPL - Free Report) reported non-GAAP earnings of 58 cents per share in the third quarter of 2018, which surpassed the Zacks Consensus Estimate by 4 cents. The figure was in line with the last reported quarter’s earnings but increased 26.1% on a year-over-year basis. Net revenues declined 4.7% sequentially but increased 14% year over year to $3.68 billion, beating the Zacks Consensus Estimate of $3.
TWLO BLT UPLD BHP BHPBF TWTR BBL PYPL BHP BHPLF
2018-10-18 zacks - 1
Twitter (TWTR - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
In the latest trading session, Twitter (TWTR - Free Report) closed at $29.55, marking a -1.07% move from the previous day. This change lagged the S&P 500's 0.03% loss on the day. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq lost 0.04%.
OLBK TWTR RLI
(Oct 18): Twitter Inc. has published data sets comprising millions of tweets, images and videos and thousands of accounts linked to operatives based in Russia and Iran, shedding light on how bad actors outside the U.S. sought to manipulate social-media discourse in their home countries and abroad.
New Delhi: London-based accelerator Entrepreneur First has earmarked $20 million to build deep technology ventures in India over the next three years, a top company executive said.
U.S. equities surged higher on Tuesday, aided by a positive outlook from Adobe (NASDAQ:ADBE) overnight. Traders focused in on extremely strong jobs data, with the JOLTS report showing more than seven million openings for the first time ever. Moreover, there are now more than a million more job openings than unemployed persons.
HMY AULGF EAT SJM TWTR AU AGG HGMCF ADBE
2018-10-17 investorplace - 2
Shares of Tesla (NASDAQ:TSLA) were on the move Tuesday, rallying more than 5%. Tesla stock held up surprisingly well last week and is now moving higher after a judge confirmed that the settlement between CEO Elon Musk and the SEC is fair and withstanding.
2018-10-17 investorplace - 1
Wall Street seems to hate Tesla (NASDAQ:TSLA) stock. It hates the cash burn and the debt. It hates CEO Elon Musk’s Twitter (NYSE:TWTR) antics, and his unique ability to consistently over-promise and under-deliver. Overall, it just doesn’t like Tesla stock.
TM TWTR TSLA
2018-10-16 investorplace - 4
Snap (NYSE:SNAP) has been a total and utter disaster. What other way can we put it? Snap stock is down a whopping 50% so far this year and more than 70% from its highs. Heck, even from its March 2017 IPO price of $17 per share, SNAP shares are down almost 60%.
GPRO FB FIT SHAK TWTR SNAP
Facebook (FB - Free Report) recently issued an update on the security breach that it had revealed on Sep 28. The company stated that of the expected 50 million users, only 30 million users’ access tokens were stolen. Facebook had announced that a security bug that was active from July 2017 in the “View As” option led to surge in unusual activities, making the company suspect it as a data breach on Sep 14.
FB GOOGL TWTR CTRL
2017-11-04 - Asif
Twitter is the best and fastest place to see what is happening and what people are talking about all around the world. Every day, instances of breaking news, entertainment, sports, politics, big events and everyday interests happen first on Twitter. Twitter is where the full story unfolds with all the live commentary and where live events come to life unlike anywhere else. The company's primary service can be accessed on a variety of mobile devices, at twitter.com and via SMS. In 2016, the company focused on positioning Twitter for long-term sustainable growth and making progress toward GAAP profitability. Specifically, the company clearly identified who Twitter is—the best and fastest place to see what’s happening in the world and what people are talking about. The company built and shipped product features that directly improved its key audience growth and engagement metrics. The company also simplified the organization to be what the company believe is more focused and efficient...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TWTR / Twitter, Inc. on message board site Silicon Investor.
|Twitter, Inc.||Twitter, Inc.||Twitter, Inc.|
|Tweeter etc. symbol TWTR IPO week of July 13th.||Tweeter etc. symbol TWTR IPO week of July 13th.||Tweeter etc. symbol TWTR IPO week of July 13th.|
as of ET